Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
A current review of COVID-19 for the cardiovascular specialist
Joshua P. Lang, MD,a Xiaowen Wang, MD,a Filipe A. Moura, MD, PhD,a Hasan K. Siddiqi, MD,a David A. Morrow, MD, MPH, a,b and Erin A. Bohula, MD, DPhil a,b

Abstract
Although coronavirus disease 2019 (COVID-19) predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes. However, whether pre-existing cardiovascular disease is an independent determinant of higher mortality risk with COVID-19 remains uncertain. Acute cardiac injury, manifest by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, occurs in up to ~60% of hospitalized patients with severe COVID-19. Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. Diffuse thrombosis is emerging as an important contributor to adverse outcomes in patients with COVID-19. Practitioners should be vigilant for cardiovascular complications of COVID-19. Monitoring may include serial cardiac troponin and natriuretic peptides, along with fibrinogen, D-dimer, and inflammatory biomarkers. Management decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19. (Am Heart J 2020;226:29-44.)

Coronavirus disease 2019 (COVID-19) has affected more than 2 million individuals worldwide. Although COVID-19 predominantly disrupts the respiratory system, there is accumulating experience that the disease, particularly in its more severe manifestations, also affects the cardiovascular system. Therefore, an understanding of how COVID-19 may influence the cardiovascular system is important for both cardiovascular practitioners and researchers. This review synthesizes the clinical evidence published to date on the cardiovascular complications of COVID-19, emerging perspectives on their pathophysiology, and evolving best practices for clinical management.

The virus
Coronaviruses (CoV) belong to a family of viruses that account for 10%-30% of all upper respiratory tract infections. The virions are large, enveloped, single-stranded RNA viruses responsible for previous epidemics as well as the common cold. In 2002, severe acute respiratory syndrome (SARS)-CoV infected at least 8,000 individuals, with ~30% of patients requiring mechanical ventilation and ~10% of cases suffering a fatal outcome. Middle East respiratory syndrome (MERS)-CoV, which was first reported in 2012 and has largely been confined to Saudi Arabia, infected greater than 2,500 patients with a case fatality rate of 35%. SARS-CoV-2, the pathogen that causes COVID-19, most closely resembles the SARS-CoV virus from 2002 and has been suspected to have initially been transmitted from bats as a natural reservoir through an intermediate animal host. It gains entry to human cells by binding to the angiotensin-converting enzyme 2 (ACE2) receptor through a transmembrane surface spike (S) glycoprotein on the viral envelope.

The transmission of the virus is thought to be primarily through large respiratory droplets and contact with contaminated fomites that then result in self-contamination of the eyes, nose, or mouth. Fecal-oral transmission may also be possible but has not been verified to be clinically important. Whereas SARS-CoV and MERS-CoV were largely transmitted through symptomatic patients, SARS-CoV-2 appears to also be transmitted by
asymptomatic individuals. At least 1 study from Asia with extensive contact tracing identified 7 clusters of cases for which spread of the virus occurred 1-3 days prior to symptom development in the source patient. In addition, it has been estimated that prior to travel restrictions in China, 86% of infections were undocumented—meaning undiagnosed and not reported.14

A study comparing the stability of SARS-CoV-2 and SARS-CoV found these virions to be stable in aerosols for hours (half-life ~1 hour) and on plastic and metal surfaces for up to 72 hours (half-life ~7 hours).15 Moreover, the National Institute of Infectious Disease in Japan reported detection of SARS-CoV-2 RNA on surfaces in the cabins of a cruise ship with infected passengers up to 17 days after they were vacated.16 Studies from the early stages of the epidemic in China, prior to implementation of full mitigation strategies, estimated a basic reproductive number (R₀) of 2.38 for SARS-CoV-2, meaning that every infected individual will, on average, spread the virus to 2 to 3 other individuals.

It has been proposed that COVID-19 progresses through several stages in its disease course.8,17 The first stage is viral infection during which constitutional symptoms, such as fever and cough, predominate. The second stage is characterized by direct viral cytotoxic effects, particular those in the respiratory tract, leading to respiratory failure and potentially acute respiratory distress syndrome. The third and final stage, which is of particular concern to cardiologists, is thought to be mediated by a hyperinflammatory response to the virus causing systemic effects, including those on the cardiovascular system.

**Pre-existing cardiovascular disease and COVID-19**

Cardiovascular risk factors and chronic cardiovascular conditions are prevalent among patients affected by COVID-19 and associated with adverse outcomes (Figure 1). In a report from the Chinese Center for Disease Control and Prevention involving 72,314 patients, baseline age, hypertension, diabetes mellitus, and known coronary artery disease were associated with adverse outcomes in COVID-19. In a survey by the Chinese Center for Disease Control and Prevention, among patients diagnosed with COVID-19, 13% had hypertension, 5% had diabetes, and 4% had pre-existing cardiovascular disease.18 In this same study, among patients who died, 40% had hypertension, 20% had diabetes, and 22% had pre-existing cardiovascular disease. Of these and a broad group of other comorbidities, cardiovascular disease was associated with the highest case fatality rate (10.5%). Several smaller, peer-reviewed case series ranging in size from ~100 to 1,000 hospitalized patients have reported similar results, with higher rates of older age, hypertension, diabetes, and cardiovascular disease in patients with more severe manifestations of COVID-19.3,4,19,20 However, whether pre-existing cardiovascular
Increasing age. The higher prevalence of these diseases with worse outcomes in COVID-19 may, in fact, predominantly be a reflection of the higher prevalence of these diseases with increasing age.

Angiotensin-converting enzyme-2 receptor

In addition to these epidemiological observations, an understanding of CoV biology, including SARS-CoV-2 entry into cells via transmembrane ACE2, has also raised the possibility of an increased risk for patients with certain underlying cardiovascular conditions. In animal models, ACE2 is upregulated with hypertension and with ACE inhibition.\(^ {23} \) Theoretically creating an increased susceptibility to CoV infection. Preclinical studies, on the other hand, suggest that ACE2 may be protective. Genetic inactivation of ACE2 of ACE2 allowed for severe lung injury in avian-influenza challenged mice and reconstitution of ACE2 mitigated the observed injury.\(^ {22} \) These considerations\(^ {10} \) were amplified by social media and led to concern in the medical community about the use of ACE inhibitors, angiotensin receptor blockers (ARB), or angiotensin receptor-neprilysin inhibitors in patients at risk for COVID-19. However, most major international cardiology professional societies, including the American College of Cardiology (ACC), American Heart association, Heart Failure Society of America, and European Society of Cardiology, have determined that, at present, the available data are insufficient to indicate that the use of these agents increases the risk of infection with SARS-CoV-2 and have issued recommendations that patients being treated with ACE/ARB/angiotensin receptor-neprilysin inhibitors should continue regardless of COVID-19 risk or infection.\(^ {23,24} \) Furthermore, there are currently 2 ongoing studies testing the hypothesis that the ARB losartan might be effective in the treatment of nonhospitalized (NCT04312009) and hospitalized patients with COVID-19 (NCT04311177). Although this area is the subject of ongoing investigation, for the time being, experts advise that taking patients with heart failure or past myocardial infarction off of these medications could lead to adverse outcomes and clinical decline.\(^ {25} \)

Cardiovascular complications of COVID-19

Acute cardiac injury

Acute cardiac injury, manifested by increased blood levels of cardiac troponin, electrocardiographic abnormalities, or myocardial dysfunction, appears to be prevalent in subgroups of hospitalized patients with COVID-19.\(^ {24,26} \) However, both the epidemiology across the clinical spectrum of patients with COVID-19 and the mechanisms of acute injury remain uncertain.

In one of the first reports to include measurement of cardiac troponin, Zhou et al found that in a series of 191 cases with laboratory-confirmed COVID-19, 17% (n = 33) developed acute cardiac injury.\(^ {4} \) Nonsurvivors had significantly higher blood levels of high-sensitivity cardiac troponin I (hsTnI) levels on admission (median 22.2 ng/L [interquartile range 5.6-83.1]) when compared with the levels in survivors (3 ng/L [1.1-5.5]). Notably, in this small cohort with serial samples, among patients who did not survive, a pattern of increasing hsTnI concentration was observed at approximately day 13 from illness onset, whereas troponin remained below reference range for individuals who survived.\(^ {20} \) These investigators speculated that acute coronary syndrome in the setting of an acute inflammatory state was a cause of injury and cited a pathologist’s examination of a patient who died of COVID-19 and had evidence of acute myocardial infarction.

Two single-center studies from academic hospitals in Wuhan, China, also described this clinical finding.\(^ {2,26} \) In a retrospective cohort of 416 patients with laboratory-confirmed COVID-19, Shi et al reported that 19.7% (n = 82) had evidence of myocardial injury as defined by an hsTnI value greater than the 99th percentile reference limit.\(^ {2} \) In-hospital mortality was 51.2% (42 of 82) among patients with myocardial injury compared with 4.5% (15 of 335) among patients without myocardial injury. Furthermore, the mortality rate was associated with the magnitude of troponin elevation. Similarly, Guo et al observed that among 187 patients hospitalized with COVID-19, 52 (27.8%) exhibited myocardial injury as demonstrated by elevation of cardiac troponin T (cTnT).\(^ {26} \) In-hospital mortality was more than 6-fold higher in patients with elevated cTnT levels than in patients with normal cTnT levels (59.6% vs 8.9%). Moreover, patients with underlying cardiovascular disease and increased cTnT levels comprised a subgroup with even higher mortality (69.4%). In contrast, patients with underlying cardiovascular disease without cTnT elevation experienced a more favorable prognosis (mortality 13.3%), albeit still higher than patients without CVD or elevated cTnT (mortality 7.6%). In this study, cTnT levels were statistically significantly correlated with the blood concentrations of C-reactive protein (CRP) (r² = 0.281) and N-terminal pro-B-type natriuretic peptide (NT-proBNP, r² = 0.376); suggesting a link to the degree of systemic inflammation and myocardial wall stress. In both studies, patients with evidence of myocardial injury were also older with a higher prevalence of coronary heart disease, cerebrovascular disease, chronic heart failure, chronic
renal failure, chronic obstructive pulmonary disease, hypertension, and diabetes. A recent case series from New York details their experience with 18 patients presenting with ST-segment elevation on electrocardiography (ECG). In this series, 14 (78%) had focal ST elevations, 8 (57%) had a reduced left ventricular ejection fraction, 5 (62%) had regional wall-motion abnormalities on echocardiography, and 6 (33%) were found to have obstructive coronary disease on coronary angiography. In this series, 72% of patients presenting with ST elevation on ECG died in hospital.

In aggregate, these data suggest that acute myocardial injury may be an important marker of disease severity and adverse prognosis in COVID-19. However, the mechanism(s) underlying this association remains unclear and plausibly multiple in etiology (Figure 2). Potential contributors to acute cardiac injury in the setting of COVID-19 include (1) acute changes in myocardial demand and supply due to tachycardia, hypotension, and hypoxemia resulting in type 2 myocardial infarction; (2) acute coronary syndrome due to acute atherothrombosis in a virally induced thrombotic and inflammatory milieu; (3) microvascular dysfunction due to diffuse microthrombi or vascular injury; (4) stress-related cardiomyopathy (Takotsubo syndrome); (5) nonischemic myocardial injury due to a hyperinflammatory cytokine storm; or (6) direct viral cardiomyocyte toxicity and myocarditis. In the setting of critical illness, these possible contributors can be very difficult to distinguish on clinical grounds. Moreover, treatment is likely to vary substantially depending on whether the suspected etiology is coronary plaque rupture or a combination of oxygen supply-demand mismatch and myocytotoxic effect of pathogens, endotoxins, cytokines, or reactive oxygen radicals induced by infectious processes.

In terms of management of these patients, the decisions should rely on the clinical assessment for the probability of ongoing myocardial ischemia, as well as alternative nonischemic causes of injury, integrating the level of suspicion for COVID-19. For example, according to a recent statement by the Society for Cardiovascular Angiography and Interventions, patients presenting with presumed ST-elevation myocardial infarction (STEMI) should be treated with primary percutaneous coronary intervention (PCI) unless there is a heightened concern for the prevalence of COVID-19 causing systematic and infrastructural delays in care. In the latter situation, it may reasonable to consider fibrinolytic therapy in a low-risk hemodynamically stable patient with STEMI if there is a limitation in availability for PCI due to stressed resources. However, at the present time, primary PCI should be used for the majority of STEMs. In the case of suspected non-STEMI, efforts should be taken to try to differentiate between an occlusive event and a demand process with tools such as electrocardiogram, echocardiogram, and coronary computed tomography angiography. The Society for Cardiovascular Angiography and Interventions statement also proposed that it is reasonable to consider deferring invasive management, especially if the patient is hemodynamically stable. Coronary angiography, when performed, may also reveal the absence of critical epicardial disease, leading to alternative diagnoses, including Takotsubo syndrome or acute myocarditis.

There is intense scientific and clinical interest in determining the underlying etiology of acute myocardial injury in COVID-19. Epidemiologic and clinical studies of influenza have demonstrated that patients with underlying coronary artery disease and risk factors for atherosclerosis have an increased risk of developing an acute coronary syndrome during acute infections. In addition, case reports have described viral myocarditis among COVID-19 patients, although none was confirmed by biopsy. Furthermore, patients with general critical illness commonly have elevated troponin levels in the absence of obvious ischemia and are at increased risk of death. The complex relationship between direct deleterious cardiovascular effects specific to SARS-CoV-2 and the cascade effects of the host immune response needs to be further elucidated. Mechanisms for myocardial injury and dysfunction in the setting of severe inflammation and cytokine storm are not currently well defined and include direct myocyte depression as a result of the inflammatory milieu as has been reported in sepsis-induced cardiomyopathy. Animal studies show that elevated cytokines and inflammatory mediators like tumor necrosis factor (TNF)-α and interleukin (IL)-6 lead to decreased contractility, possibly mediated through calcium-dependent pathways.

Pericarditis and myocarditis

Myocarditis and pericarditis are potential cardiovascular manifestations of COVID-19, although available evidence is mixed and largely based on single-patient case reports. A case report from Hu et al reports the evaluation of a 37-year-old man in China who presented with chest pain, dyspnea, and diarrhea and was found to have fulminant myocarditis with acute elevations in cTnT (>10,000 ng/L) and NT-proBNP (>20,000 ng/L) and left ventricular ejection fraction (LVEF) of 27%, with clean coronaries on computed tomography coronary angiography. He was treated with intravenous immunoglobulin (IVIG) and methylprednisolone for immunosuppression, along with supportive care with vasopressors and diuretics, and ultimately had recovery of LV function (LVEF 66%) and improved biomarkers. A subsequent case report from Northern Italy described a 53-year-old woman with confirmed SARS-CoV-2 infection who presented with fatigue, elevated cardiac biomarkers, ECG changes, and a
Representation of the possible mechanisms of acute myocardial injury related to COVID-19. (A) Myocarditis; (B) type 2 MI (left) and type 1 MI (right); (C) contraction bands in stress cardiomyopathy; (D) microvascular dysfunction from microthrombi and endothelial injury; and (E) cytopathic injury in cytokine storm.
within cytopathic interstitial cells of the myocardium but endomyocardial biopsy revealed coronavirus particles presenting with COVID-19 and cardiogenic shock, limited. In a report of a 69-year-old woman with COVID-19 and heart failure, it remains possible that, in some cases, SARS-CoV-2 causes myocardial dysfunction through viral myocarditis; however, at the point of this writing, pathological evaluation of suspected cases of COVID-19-associated myocarditis, including the possibility of viral entry into cardiomyocytes, is extremely limited. In a case report of a 69-year-old woman presenting with COVID-19 and cardiogenic shock, endomyocardial biopsy revealed coronavirus particles within cytopathic interstitial cells of the myocardium but not in myocytes or endothelial cells. In a 43-year-old woman with COVID-19 and ST elevation with mild left ventricular dysfunction, endomyocardial biopsy demonstrated diffuse T-lymphocytic inflammatory infiltrates with interstitial edema and limited foci of necrosis without SARS-CoV-2 within the myocardium, rendering a final diagnosis of a virus-negative lymphocytic myocarditis. The coronary microvasculature and endothelium may be at risk for viral entry due to ACE2 expression on these vascular cells. In fact, a pathologic study showed direct evidence of viral invasion and resulting apoptosis in epithelial cells of various organs using electron microscopy.43

Heart failure and cardiogenic shock

Heart failure and cardiogenic shock appear to be important causes of morbidity and mortality in COVID-19. In a study of 191 patients with confirmed COVID-19 from 2 Chinese hospitals, 23% (n = 44) of patients had a clinical diagnosis of heart failure.4 Of the patients who died during the study, 52% (n = 28) had developed heart failure versus 12% (n = 16) with heart failure among survivors (P < .0001). In another retrospective case series of 150 patients with COVID-19 from 2 Chinese institutions, 33% (n = 22) of deaths were attributed to respiratory failure with myocardial damage or heart failure, with an additional 7% reported as heart failure without respiratory failure.44 In a clinical review of these deaths, the researchers suggested that fulminant myocarditis may have been the etiology of the heart failure; however, no additional diagnostic details were included.

Thrombosis/venous thromboembolic disease

Diffuse thrombotic disease is an emerging concern in COVID-19. Other respiratory viral illnesses have been reported to predispose to patients to venous thromboembolism (VTE). Also, in the prior experience with SARS, autopsies showed fibrin thrombi in 85% of cases, with 71% of these associated with pulmonary infarction. It is plausible that SARS-CoV-2 infection also increases VTE risk. A preliminary report identified microthrombi in the pulmonary vasculature in an autopsy of a patient who expired from COVID-19. Another study showed that patients admitted with COVID-19 have high clinical risk scores for thromboembolic events. An early report of thromboembolic events in COVID-19 from a case series of all patients with proven COVID-19 pneumonia that were admitted to any of 3 ICUs in the Netherlands found 31 thromboembolic events in this cohort (n = 184), of which most were pulmonary embolisms (n = 25). Of note, all of these patients were reportedly receiving pharmacological prophylaxis with low-molecular weight heparin, albeit there was underdosing relative to typical dosing at US hospitals in 2 of the 3 centers involved. Changes in coagulation parameters in patients hospitalized with COVID-19 are well documented, with remarkable elevation in D-dimer. In one of the largest retrospective studies to date of hospitalized patients with COVID-19 (n = 191), nonsurvivors had a more
pronounced increase in D-dimer levels during the course of their disease, and increased levels (>1 g/L) predicted higher adjusted odds of in-hospital death (odds ratio 18.4, 95% CI 2.6-128.6, P = .003).\textsuperscript{4} In another retrospective study (n = 185) comparing COVID-19 survivors versus nonsurvivors, nonsurvivors were shown to have higher D-dimer and fibrin degradation product levels on admission.\textsuperscript{51} These differences became more accentuated during serial daily measurements, and by later stages, 71.4% of nonsurvivors met criteria for disseminated intravascular coagulation.\textsuperscript{51} This profile of elevated breakdown of fibrin products has also been previously described in hospitalized SARS.\textsuperscript{52} The presence of antiphospholipid antibodies was reported in 3 patients with severe COVID-19 and multiple cerebral infarctions (including 1 with concurrent critical limb ischemia). However, the report did not account for other therapies that are known to cause preanalytical challenges in the interpretation of these studies such as blood transfusions. The role of antiphospholipid antibodies in the pathogenesis of thromboembolism remains unclear.\textsuperscript{53}

The mechanisms involved in possible thrombotic complications in COVID-19 are uncertain. The regulation of pro- and antithrombotic pathways is complex and contingent on both host and pathogen-related properties.\textsuperscript{46} Specific mechanistic studies with SARS-CoV-2 are still lacking, but a prior study of SARS-CoV demonstrated that infection of mice increases proinflammatory (IL-1B, TNF-α, and IL-6) and profibrotic (transforming growth factor B, connective tissue growth factor, and platelet-derived growth factor) cytokine transcripts as well as upregulates genes associated with induction of a procoagulant state and other fibrinolysis pathway components.\textsuperscript{54}

Medically ill patients with COVID-19 should receive adequately dosed pharmacological prophylaxis for VTE and receive systemic anticoagulation for established VTE according to guideline recommendations.\textsuperscript{55} Given interaction of antiviral therapies with liver function, some academic centers have developed guidelines that suggest to switch direct oral anticoagulants or warfarin to IVIG, and convalescent serum from patients recovered from COVID-19.\textsuperscript{56,57} Other efforts have been directed toward modulation of the host’s inflammatory responses, using agents such as corticosteroids, tocilizumab, sarilumab, interferon-γ, IVIG, and convalescent serum from patients recovered from COVID-19.\textsuperscript{58-62} Other trials are still ongoing in the United States (NCT04292899, NCT04292730). In a cohort of 61 hospitalized patients with oxygen saturation of 94% or block and ventricular fibrillation.\textsuperscript{57} The causal mechanism is unclear but, analogously to acute cardiac injury, could be secondary to myocarditis, myocardial stress, or ischemia.

### Possible pharmacotherapy for COVID-19

At the time of this writing, there are no pharmacotherapies specifically approved for the management of SARS-CoV-2 or the complications of COVID-19. However, in addition to the supportive management described in the section that follows, clinical consideration has been given to off-label use of medications directed toward the virus itself (Table I) by targeting endocytosis of the virus, such as with hydroxychloroquine; by RNA chain termination using antiviral agents such as remdesivir, galidesivir, favipiravir, and ribavirin; or by inhibiting protein synthesis using lopinavir/ritonavir.\textsuperscript{58,62} Other efforts have been directed toward modulation of the host’s inflammatory responses, using agents such as corticosteroids, tocilizumab, sarilumab, interferon-γ, IVIG, and convalescent serum from patients recovered from COVID-19.\textsuperscript{56,58-60} However, these agents have the potential for deleterious side effects, including cardiac effects such as QT prolongation, cardiomyopathy, or fluid retention. Therefore, while awaiting further data, in our view, all patients with COVID-19 should be considered first for eligibility for participation in a clinical trial before being entertained for the off-label use of antiviral and anti-inflammatory therapies that are experimental in this population. More than 500 trials are ongoing testing novel or repurposed potential therapeutics for SARS-CoV-2. A listing of selected randomized trials is provided in Table II.

### Remdesivir

Remdesivir, an adenosine analogue, was initially developed for treatment of Ebola virus infection. It binds to the active site on the RNA-dependent RNA polymerase of viral RNAs, causing premature termination of RNA replication. It has been shown to inhibit viral replication of SARS-CoV, MERS-CoV, and SARS-CoV-2 in vitro studies.\textsuperscript{63-65} Remdesivir improved the outcome of treatment of MERS-CoV infection in a nonhuman primate model based on clinical signs and viral load in lung tissues.\textsuperscript{66} There are also case reports of using remdesivir in humans.\textsuperscript{67} Two clinical trials in China, 1 in patients with mild and moderate symptoms (NCT04252664) and 1 in patients with severe symptoms (NCT04257656), have been terminated because of lack of patient enrollment with improved control of the epidemic in that country. Several trials are still ongoing in the United States (NCT04292899, NCT04292730). In a cohort of 61 hospitalized patients with oxygen saturation of 94% or...
less on ambient air who received remdesivir for compassionate use, 57% of patients receiving mechanical ventilation were successfully extubated, and 13% of the patients died. The absence of a control group is a critical limitation of this preliminary study. Although more comprehensive data on cardiac toxicities have yet to be published, there is a report of hypotension followed by cardiac arrest during a loading dose in a patient being treated for Ebola. Elevation of hepatic transaminases has been reported in patients receiving remdesivir, raising concerns for hepatotoxicity in patients who are already critically ill. Compassionate use of remdesivir outside of clinical trials is limited.

### Chloroquine and hydroxychloroquine

Chloroquine has been used as an antimalarial drug since the 1930s. Because of their immunomodulatory properties, chloroquine and its hydroxyl analogue hydroxychloroquine are also used to treat rheumatoid arthritis and systemic lupus erythematosus. These drugs have also been shown to interfere with endosome-mediated viral entry. They have also been shown to decrease proinflammatory cytokines, possibly decreasing the severity of cytokine storms. Chloroquine has been shown to have in vitro antiviral activities against SARS-CoV-2. An initial small, nonrandomized, open-label French study, in which chloroquine and azithromycin appeared to have faster than expected viral clearance, has since been retracted because of methodological issues. A large French study, in which chloroquine and azithromycin appeared to have faster than expected viral clearance, has since been retracted because of methodological issues. In a randomized trial of 62 patients in Shanghai, China, the treatment group (hydroxychloroquine 200 mg twice daily between days 1 and 5) had shorter fever and cough duration. Several larger randomized trials are ongoing in China and the United States that will provide more robust evidence on the efficacy of chloroquine and hydroxychloroquine. Of note, these medications can cause QT prolongation and potential risks for torsades de pointes especially when used concomitantly with other QT-prolonging medications; careful monitoring is warranted. The ACC has suggested protocols for monitoring both in the clinical trials and inpatient and outpatient clinical care settings. Hydroxychloroquine has also been associated with a higher risk of hypoglycemia in diabetes patients. At the time of this writing, one of the

### Table I. Potential therapies targeting SARS-CoV-2

| Medication       | Proposed mechanism | Dosing                          | Adverse effects                                      | Cardiac monitoring                     | Key clinical trials                  |
|------------------|--------------------|---------------------------------|------------------------------------------------------|----------------------------------------|--------------------------------------|
| Remdesivir       | Inhibits viral RNA-dependent RNA polymerase; reduces viral replication | 200 mg on day 1, then 100 mg daily for 5-10 d | Limited data; reports of hypotension, nausea, vomiting; elevation of liver enzymes. | Monitor hemodynamics, with infusion especially when used with other medication | NCT04292899, NCT04292730, NCT04315948, NCT04280705 |
| Chloroquine      | Inhibits 3-chymotrypsin-like protease; reduces viral replication | 400/100 mg twice daily for up to 14 d | Nausea, vomiting, diarrhea, pancreatitis, hepatitis, QTc prolongation | Monitor QTc especially when used with other medication | NCT04328012 |
| Hydroxychloroquine | Inhibits viral entry by interfering with endocytosis; modulates host immune response | 200 mg BID for 10 d | Nausea, vomiting, hemolysis (G6PD deficient), QTc prolongation, hypoglycemia, retinal toxicity | Monitor QTc especially when used with other medication | NCT04328467, NCT04341441, NCT04333732, NCT04342169, NCT04334382, NCT04341727, NCT04345692, NCT04335552 |
| Tocilizumab      | Binds IL-6 receptor and inhibits IL-6 activation, modulates host immune response | 400 mg or 8 mg/kg for 4 d | Similar to chloroquine but less common increased risks of infection (including tuberculosis), hypertension, increased AST, hypersensitivity, volume retention | Monitor QTc especially when used with other medication | NCT04310228, NCT04346535, NCT04332094, NCT04320615 |
| Sarilumab        | Binds IL-6 receptor and inhibits IL-6 activation, modulates host immune response | Per trial protocol | Increased AST, hypersensitivity, increased triglycerides and LDL-C, neutropenia | Monitor QTc especially when used with other medication | NCT04327388, NCT04321993, NCT04345289 |
| Convalescent plasma | Reduces viral replication in host | Per trial protocol | Transfusion reactions | Monitor QTc especially when used with other medication | NCT04343755, NCT04348656, NCT04342182 |
### Table II. Selected trials of pharmacotherapies for COVID-19 prevention or treatment

| Trial title                                                                 | Study type                  | Population                                      | Intervention                                                                 | Key primary outcome                                      | N          | Clinical trial #  |
|----------------------------------------------------------------------------|-----------------------------|------------------------------------------------|----------------------------------------------------------------------------|----------------------------------------------------------|------------|------------------|
| **Chloroquine/Hydroxychloroquine**                                         |                             |                                                 |                                                                            |                                           |            |                  |
| Pre-exposure Prophylaxis for SARS-CoV-2: A Pragmatic Randomized Clinical Trial | Randomized, double blind   | HCWs at high risk for COVID-19                 | HCQ once weekly vs HCQ twice weekly vs control                               | COVID-19–free survival                                   | 3500       | NCT04328467      |
| Will HCQ Impede or Prevent COVID-19: WHIP COVID-19 Study                   | Randomized, double blind   | HCWs without COVID symptoms                    | HCQ daily vs HCQ weekly vs placebo vs nonrandomized active comparator        | Reduction in the number of COVID-19 infections in HCWs  | 3000       | NCT04341441      |
| An International, Multi-site, Bayesian Platform Adaptive, Randomized, Double-blind, Placebo-Controlled Trial Assessing the Effectiveness of Varied Doses of Oral CQ in Preventing or Reducing the Severity of COVID-19 in Healthcare Workers | Randomized, double blind   | HCWs with symptoms of COVID-19                   | HCQ/HCO low dose vs mid dose vs high dose vs placebo                        | Symptomatic COVID; peak severity of COVID-19 over study period | 55,000     | NCT04333732      |
| **Outpatients**                                                            |                             |                                                 |                                                                            |                                           |            |                  |
| HCQ for Outpatients With Confirmed COVID-19                                | Randomized, open label      | Outpatient                                      | HCQ vs placebo                                                               | Duration of viral shedding                             | 400        | NCT04342169      |
| Hydroxychloroquine vs Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT): A Prospective Pragmatic Trial | Randomized, open label      | Outpatient                                      | HCQ vs azithromycin                                                         | Hospitalization within 14 d                            | 1550       | NCT04334382      |
| **Hospitalized patients**                                                  |                             |                                                 |                                                                            |                                           |            |                  |
| WU 352: Open-label, RCT of HCQ Alone or HCQ Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS-CoV-2 Infection | Randomized, open label      | Hospitalized                                     | HCQ vs HCO + azithromycin vs CQ vs CQ + azithromycin                         | Hours to recovery AND free from MV/ death               | 500        | NCT04341727      |
| A RCT of the Safety and Efficacy of HCQ for the Treatment of COVID-19 in Hospitalized Patients | Randomized, open label      | SpO2 ≤ 94%, hospitalized                        | HCQ vs SoC CQ vs HCO vs azithromycin                                        | Clinical status on 7-point ordinal scale at day 15      | 350        | NCT04345692      |
| Pragmatic Factorial Trial of HCO, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection | Randomized, open label      | Hospitalized                                     | HCQ + azithromycin                                                         | WHO Ordinal Scale at 14 d                               | 500        | NCT04335552      |
| **Remdesivir**                                                             |                             |                                                 |                                                                            |                                           |            |                  |
| A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Severe COVID-19 | Randomized, open label      | Hospitalized, SpO2 ≤ 94% or requiring O2, not on MV | Remdesivir vs SoC                                                                 | Odds ratio for improvement on a 7-point ordinal scale on day 14 | 6000       | NCT04292899      |
| A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate COVID-19 Compared to Standard of Care | Randomized, open label      | Hospitalized, SpO2 > 94% on room air            | Remdesivir vs standard treatment Remdesivir vs lopinavir/ritonavir + interferon β1A vs HCQ | Odds ratio of improving on a 7-point ordinal scale on day 11 | 1600       | NCT04292730      |
| **Lopinavir**                                                              |                             |                                                 |                                                                            |                                           |            |                  |
| Comparison Of Therapeutics for Prevention or Treatment of COVID-19          | Randomized, Hospitalized    | Lopinavir/ritonavir                              | COVID-19 Ordinal                                                            |                                           | 4000       | NCT04328012      |

(continued on next page)
randomized trials studying chloroquine (NCT04323527) was stopped early because of a concern for excess arrhythmias.76

| Trial title                                                                 | Study type          | Population               | Intervention                          | Key primary outcome                     | N     | Clinical trial #         |
|----------------------------------------------------------------------------|---------------------|--------------------------|---------------------------------------|-----------------------------------------|-------|--------------------------|
| Hospitalized Patients Infected With SARS-CoV-2 In a Pragmatic aDaptive   | double blind        | HCO, losartan, placebo   | Severity Scale (NCOSS) at 60 d         |                                         | 150   | NCT04310228              |
| randomized randoMizED Clinical Trial During the COVID-19 Pandemic          |                     |                          |                                       |                                         |       |                          |
| Tocilizumab                                                               |                     |                          |                                       |                                         |       |                          |
| Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus     | Randomized, open    | Hospitalized Tocilizumab  | ICU care with MV or death              |                                         | 398   | NCT04346355              |
| Disease 2019—a Multi-Center,                                             | label               | Medical Trial vs Tocilizumab + get vs HCQ + azithromycin             |                                       |                                         |       |                          |
| Randomized and Controlled Clinical Study                                   |                     |                          |                                       |                                         |       |                          |
| Tocilizumab                                                               | Randomized, open    | Moderate to severe       | Sarilumab vs placebo Clinical status   |                                         | 300   | NCT04327388              |
| COVID-19 in Hospitalized Patients                                        | label               | COVID19                  | at day 15 on 7-point ordinal scale     |                                         |       |                          |
| Sarilumab                                                                 |                     |                          |                                       |                                         |       |                          |
| An Adaptive Phase 2/3, Randomized, Double-Blind, Placebo Controlled Study  | Randomized, double  | Hospitalized Sarilumab    | Time to resolution of fever for ≥48 h or D/C (Ph 2); severity on ordinal scale (Ph 3) |                                         | 1000  | NCT04321993              |
| Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients With | blind                | Medical Trial Sarilumab   |                                         |                                         |       |                          |
| COVID-19                                                                  |                     |                          |                                       |                                         |       |                          |
| Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in          | Randomized, double  | Moderate to severe       | Convalescent serum vs sarilumab vs IV  | In-hospital mortality at 60 d           | 1500  | NCT04345289              |
| Hospitalized Patients                                                      | blind                | COVID19                  | placebo vs HCQ vs baricitinib vs oral  |/placebo                                |       |                          |
| Sarilumab                                                               |                     |                          | placebo                              |                                         |       |                          |
| ConvaClescent plasma                                                      |                     |                          |                                       |                                         |       |                          |
| Phase IIa Study Exploring the Safety and Efficacy of ConvaClescent Plasma | Single group         | Hospitalized, moderate   | Mechanical ventilation at 7 d or death  |                                         | 55    | NCT04343755              |
| From Recovered COVID-19 Donors Collected by Plasmapheresis as Treatment   |                     | symptoms                 |                                       |                                         |       |                          |
| for Hospitalized Subjects With COVID-19 Infection                          |                     | Hospitalized, intubation  |                                       |                                         |       |                          |
| A Randomized Open-Label Trial of ConvaClescent Plasma for Hosp            | Randomized, open    | supplemental oxygen      | ConvaClescent plasma vs SoC Intubation or death in hospital |                                         | 1200  | NCT04346566              |
| Adults With Acute COVID-19 Respiratory ILLness                            | label               |                          |                                       |                                         |       |                          |
| ConvaClescent Plasma Therapy From Recovered Covid-19 Patients as           |                     |                          |                                       |                                         |       |                          |
| Therapy for Hospitalized Patients With Covid-19                            |                     |                          |                                       |                                         |       |                          |

38 Lang et al

HCW, denotes healthcare worker; HCO, hydroxychloroquine; CQ, chloroquine; MV, mechanical ventilation; SoC, standard of care.

Lopinavir-ritonavir

Lopinavir is a human immunosuppression virus-1 protease inhibitor that is used in combination with
ritonavir to treat human immunosuppression virus infections. During the 2003 SARS pandemic, in an open-label study, lopinavir-ritonavir, ribavirin, and corticosteroid appeared to have lower rate of acute respiratory distress syndrome or death in the treatment group compared with a historical control group who received only ribavirin and a corticosteroid. In an open-label, randomized, controlled trial involving 199 seriously ill patients with COVID-19 in China, compared with standard care, treatment with lopinavir-ritonavir did not result in clinical improvement or reduced mortality. Lopinavir-ritonavir causes significant gastrointestinal adverse effects, can cause pancreatitis and hepatitis in patients with pre-existing liver disease, and prolongs the QT interval.

**Tocilizumab and sarilumab**

Tocilizumab and sarilumab are IL-6 antagonists. Initially approved for treatment of rheumatoid arthritis, tocilizumab is also used for treatment of cytokine release syndrome in patients treated with chimeric antigen receptor T-cell therapy. Previous studies have found increased levels of cytokines, such as IL-6, IL-8, and TNF-α, in patients with SARS and MERS. Similar increase in inflammatory markers has also been observed in patients with COVID-19, suggesting cytokine storm as a possible underlying contributor to the end-organ dysfunction seen in this disease. Given these observations, tocilizumab and sarilumab have been proposed as candidate therapies for patients with severe COVID-19. Both medications have been approved for clinical trials (Table 1). Tocilizumab has been shown to increase fluid retention and potentially increase lipid profile, but was not found to increase risk of cardiovascular complications in large cohort studies. Both medications can cause immunosuppression and increased risks of serious infections including tuberculosis, hypersensitivity, and increased liver enzymes. Sarilumab can also cause decreased neutrophil and platelet counts, and increased low-density lipoprotein and tryglycerides.

**Convalescent plasma**

Convalescent serum from individuals who have recovered from viral infection has been used to treat patients with acute viral infections, such as Ebola, H5N1, and H1N1, although efficacy results were mixed. Convalescent serum was also used during the SARS pandemic and was found to be associated with higher 22-day discharge rate (74% vs 19%, \( P < .001 \)). In a more recent case series, 5 critically ill patients with COVID-19 treated with convalescent serum showed clinical improvement; however, larger studies with more rigorous design are needed. Clinical trials are ongoing to test the feasibility and efficacy of using convalescent plasma (Table 1).

**Supportive management and cardiovascular assessment of patients with COVID-19**

Cardiologists involved in the care of patients with COVID-19 face a wide range of care decisions in the context of a rapidly evolving but, as yet, modest evidence base (Figure 3). In addition to experimental antiviral and anti-inflammatory therapies discussed in the next section of this review, management is focused on supportive care aimed at mitigating the respiratory insufficiency that predominates in COVID-19 as well as the consequences of other end-organ injury resulting from the viral infection.

Key principles for management of respiratory failure in COVID-19 include (1) caution regarding the use of aerosolizing devices for delivery of supplemental oxygen due to risk of viral transmission; (2) low tidal volume mechanical ventilation and high positive end-expiratory pressure; and (3) liberal use of prone ventilation, including consideration of “self-proning” in the nonintubated patient. Guidance from the Surviving Sepsis Campaign COVID-19 Subcommittee includes use of nasal cannula when patients’ \( \text{SpO}_2 \) drops below 90%. When respiratory failure worsens beyond the support available by nasal cannula, the use of either high-flow nasal cannula or noninvasive positive pressure ventilation must be balanced against the risk of aerosolization, and thus, both have been classified as a weak recommendation based on low-quality evidence and risk. Use of a nonrebreather or Venturi masks is believed to maximize oxygen delivery without significant aerosolization. In many centers, patients are intubated earlier in the disease course, which may help avoid emergent intubation and excess risk to health care workers. Once intubated, adherence to general principles of ventilation for patients with acute respiratory distress syndrome is recommended with low tidal volumes (4.8 mL/kg of ideal body weight), inspired fraction of oxygen \( \leq 50% \) as soon as achievable, and higher positive end-expiratory pressure with the aim to mitigate the risk of high driving pressure (barotrauma) or tidal volumes (volutrauma) and of oxygen-related toxicity.

COVID-19 is known to be a systemic illness with numerous complications other than cardiac. Abnormal liver enzymes are common, but acute liver injury, defined as 3 times the upper limit of normal, appears to occur largely as a result of shock and critical illness. Acute kidney injury occurs at high rates for those hospitalized with severe manifestations of the disease. Renal replacement therapy is needed in approximately 5% of patients with COVID-19 admitted to ICUs. For critically ill patients, disseminated intravascular coagulation has been noted, but disturbances of coagulation in most patients with COVID-19 are characterized
COVID-19 for the cardiologist: Monitoring for cardiovascular complications and supportive management. PT, prothrombin time; PTT, partial thromboplastin time; TTE, transthoracic echocardiogram; cMRI, cardiac magnetic resonance imaging; CT-PE, computed tomography pulmonary angiogram; MCS, mechanical circulatory support; GDMT, guideline-directed medical therapy.

by a hypercoagulable profile with very high D-dimer and fibrinogen, possibly predisposing patients to macrovascular thrombosis. Standard guidelines for anticoagulation for prophylaxis of venous thromboembolism in acute medical illness should be followed assiduously, and in some centers, consideration is given to more intensive prophylactic anticoagulation. Lastly, potential drug-drug interactions between antiplatelet agents and anticoagulants with investigational COVID-19 therapies ought be considered when caring for patients requiring these cardiovascular therapies. As yet, there are no evidence-based guidelines for monitoring of cardiovascular complications of COVID-19. Because of the observation that patients with COVID-19 with significantly elevated cardiac biomarkers (cardiac troponin, natriuretic peptides, CRP, D-dimer) tend to have worse outcomes, some centers are routinely measuring such biomarkers in a serial manner. This approach is commensurate with the view that prognostic information in trending serial biomarkers may be useful for clinicians in better monitoring and predicting the disease course, helping to triage patients to appropriate level of care and to inform the tailoring of vasoactive agents in shock. In contrast, the ACC published a statement advising against routine testing of troponins and BNP in patients admitted with COVID-19, arguing that these tests should only be used when there is evidence of either myocardial infarction or new heart failure. The routine use of cardiac imaging, including echocardiography, has been challenging for institutions trying to balance the risk for health care workers exposed to these patients versus the clinical utility of these tests; consequently, clinicians are being advised to use point-of-care ultrasound when possible. Under normal
circumstances, in a disease that is known to cause myocardial dysfunction and heart failure, a patient with high cardiac biomarkers and evidence of volume overload would likely prompt a transthoracic echocardiogram; however, in the setting of COVID-19, careful consideration should be given to whether the imaging study will affect management and whether or not a point-of-care ultrasound is applicable as a screening tool. If acute cardiac diseases or complications are identified, treatment for heart failure, cardiogenic shock, and myocarditis should generally follow clinical practice guidelines irrespective of COVID-19, including the use of inotropes and mechanical circulatory support when appropriate in the context of the patient’s overall prognosis and availability of resources. Invasive evaluation for suspected ongoing myocardial ischemia has been discussed in an earlier section of this review.

Summary
COVID-19 is more than a respiratory illness; it is now understood to have broad systemic effects, including cardiovascular manifestations (Figure 1). Cardiac injury may occur through possible ischemic and nonischemic mechanisms (Figure 2). Diffuse microvascular and macrovascular thrombosis is emerging as a recognized complication and possibly central pathology of COVID-19. Moreover, with the expanding use of antiviral therapies, medication-induced cardiac toxicity may become increasingly common. Heart failure and cardiogenic shock are known to occur as a result of COVID-19, either by an inflammatory cardiomyopathy or by viral myocarditis, or possibly due to ischemic injury. Protocols for monitoring and treating these entities remain subject to investigation. Although what we know about the epidemiology of COVID-19 has expanded rapidly, additional rigorous investigation is needed to more completely elucidate the cardiovascular complications of COVID-19 and provide guidance for their treatment.

Disclosure
The authors have no relevant disclosures to report.

References
1. The Johns Hopkins Coronavirus Resource Center. Coronavirus COVID-19 global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html. Accessed April 1, 2020.
2. Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. JAMA Cardiology: China. 2020.
3. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China JAMA 2020;323(11):1061-9.
4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62.
5. Paules CI, Marston HD, Fauci AS. Coronavirus infections—more than just the common cold. JAMA 2020;323(8):707-8.
6. Centers for Disease Control and Prevention. In the absence of SARS-CoV transmission worldwide: guidance for surveillance, clinical and laboratory evaluation, and reporting. 2005. https://www.cdc.gov/sars/surveillance/absence.html. Accessed 02 April 2020.
7. Centers for Disease Control and Prevention. MERS clinical features. 2019. https://www.cdc.gov/coronavirus/mersclinical-features.html. Accessed 02 April 2020.
8. Atri D, Siddiqi HK, Lang J, et al. COVID-19 for the cardiologist: a current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC: Basic to Translational Science 2020;4:443.
9. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv 2020:2020.01.31.929042.
10. Centers for Disease Control and Prevention. How coronavirus spreads. 2020. https://www.cdc.gov/coronavirus/2019ncov/prepare/transmission.html. Accessed 02 April 2020.
11. Ong SWX, Tan YK, Chia PY, et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA 2020;323(16):1610-2.
12. Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020;158(6):1831-3.
13. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020;323(18):1843-4.
14. Li R, Pei S, Chen B, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 2020;368(6490):489-93.
15. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England Journal of Medicine 2020;382(16):1564-7.
16. Moriarty LPM, Marston BJ, et al. Public health responses to COVID-19 outbreaks on cruise ships—worldwide, February-March 2020. MMWR Morb Mortal Wkly Rep 2020;69:347-52.
17. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant.
18. Chinese Center for Disease Control and Prevention. Tracking the epidemic—National Health Commission update. 2020. http://weekly.chinacdc.cn/news/TrackingtheEpidemic.htm. Accessed 02 April 2020.
19. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Internal Medicine 2020.
20. Guan W-j, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine 2020.
21. Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin-angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2011;20(1):62-8.
22. Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 2014;5:3594.
23. HFSA/ACC/AHA. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. https://www.
24. European Society of Cardiology. Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020. Accessed 02 April 2020.

25. Vaduganathan M, Vardeny O, Michel T, et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. New England Journal of Medicine 2020;382(17):1659-93.

26. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020, e201017, https://doi.org/10.1001/jamacardio.2020.1017.

27. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with Covid-19—a case series. New England Journal of Medicine 2020, NEJMc2009020, https://doi.org/10.1056/NEJMc2009020.

28. Agewall S, Giannitsis E, Jemberg T, et al. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J 2011;32(4):404-11.

29. Szerlip M, Anwaruddin S, Aronow HD, Cohen MG, Daniels MJ, Delghi A, et al. Considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020, https://doi.org/10.1001/jamacardio.2020.1017.

30. Fried Justin A, Ramasubbu K, Bhatt R, Topkara Veli K, Clerkin Kevin J, Horn E, et al. The variety of cardiovascular presentations of COVID-19. Circulation;0(0).

31. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med 2018;378(4):345-53.

32. Nguyen JT, Yang W, Ito K, et al. Seasonal influenza infections and cardiovascular disease mortality. JAMA Cardiol 2016;1(3):274-81.

33. Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020, ehaa190, https://doi.org/10.1093/eurheartj/ehaa190.

34. Inciardi RM, Lupi L, Zaccione G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020, https://doi.org/10.1001/jamacardio.2020.1096.

35. Lim W, Qushmaq I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med 2006;166(22):2446-54.

36. Kumar A, Thota V, Dee L, et al. Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183(3):949-58.

37. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 2004;363(9404):203-9.

38. Hambai IA, Edgecomb J, LaBarge K, et al. Disregulation of intracellular calcium transporters in animal models of sepsis-induced cardiomyopathy. Shock 2015;43(1):3-15.

39. Zeng J, Liu Y-X, Yuan J, et al. First case of COVID-19 infection with fulminant myocarditis complication: case report and insights. 2020.

40. Zheng Y-Y, Ma Y-T, Zhang J-Y, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17(5):259-60, https://doi.org/10.1038/s41569-020-0360-5.

41. Tavazzi G, Pellegrini C, Maurelli M, Bellato M, Sciuitti F, Bottazz A, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. European Journal of Heart Failure 2020;22(1):32-71.
50. Lang ET, Arentz M, Yim E, et al. Clinical review: the natural history of critically ill patients with COVID-19. JAMA Intern Med 2020;180(7):910-2.

51. Lee SK, Sim SH, Park Y, et al. Clinical characteristics and outcome of COVID-19 patients treated with convalescent plasma. J Korean Med Sci 2020;35(17):e190.

52. Li J, Wang X, Liu G, et al. Convalescent plasma therapy for COVID-19: a clinical study. J Med Virol 2020;92(7):2795-8.

53. Li Y, Wang J, Zhang Y, et al. Convalescent plasma as salvage therapy for critically ill patients with COVID-19: a randomized clinical trial. Science 2020;370(6522):666-9.

54. Li Z, Chen C, Tong J, et al. Convalescent plasma for COVID-19: a meta-analysis. JAMA Intern Med 2020;180(7):964-72.

55. Lu Y, Chen Y, Qiu J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. BMJ Open 2020;10(7):e038637.

56. Ma L, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Clin Virol 2020;128:104418.

57. Meng X, Wang X, Xu F, et al. Convalescent plasma for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2338-50.

58. Niu X, Cao X, Zhang B, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Clin Virol 2020;127:104454.

59. Peng J, Wang X, Sun Y, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2350-60.

60. Qin Y, Sun Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2361-72.

61. Sun Y, Li J, Qin Y, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2373-83.

62. Wang X, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2384-94.

63. Wu M, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2395-406.

64. Yang H, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2407-16.

65. Zhang W, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2417-26.

66. Zhang Y, Wang X, Sun Y, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2427-37.

67. Zhao J, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2438-49.

68. Zhou X, Chen Y, Li J, et al. Convalescent plasma therapy for COVID-19: a systematic review and meta-analysis. J Med Virol 2020;92(8):2450-60.
96. Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and kidney failure in the acute care setting: our experience from Seattle. Am J Kidney Dis.

97. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020;27284.

98. Chapman Andrew R, Adamson Philip D, Shah Anoop SV, et al. High-sensitivity cardiac troponin and the universal definition of myocardial infarction. Circulation 2020;141(3):161-71.

99. Januzzi JL. Troponin and BNP Use in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/18/15/25/troponin-and-bnp-use-in-covid19 2020. Accessed April 17, 2020.

100. American Society of Echocardiography. ASE statement on protection of patients and echocardiography service providers during the 2019 novel coronavirus outbreak 2020. https://www.asecho.org/ase-statement-covid-19/9 Accessed 17 April 2020.